What can COVID-19 Teach us about Respiratory Disease? COVID19 SARSCoV2 Coronavirus
Forms of respiratory diseasesThe future of respiratory diseases Until recently, COVID-19 seemed to be a harmless pathogen of minor outbreaks of unremarkable and mild acute respiratory diseases. At the same time, many similar microorganisms lived in natural reservoirs - in the body of exotic Asian animals.
More than 200 million respiratory tract infections occur each year globally . Only less than a third of them go through health workers, primarily with the outpatient network, which accounts for more than 10% of all visits to the office of a primary care doctor. The problem of high morbidity and significant economic losses increases significantly due to complications, which can often end in death. Pneumonia and influenza together are the fourth leading cause of death in people aged 65 and over.
Given the similarity of the symptoms of respiratory infections, it is very important for adequate therapy to timely separate COVID-19 and seasonal SARS and influenza, as well as bacterial pathology. Next, doctors struggle with the syndromes caused by the disease. Treatment may require anti-inflammatory therapy, therapy aimed at eliminating coagulation disorders, and, finally, therapy aimed at correcting hypoxemia or respiratory failure. Of course, each patient may have their own unique features over the course of the disease, so the therapy in each case will be different.
The emergence of pulmonary fibrosis Fibrosis is the body's defense response to inflammation or injury. It occurs in approximately 10-15% of patients who recover from viral pneumonia associated with COVID-19.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Interrupting treatment of patients on immune-suppressing medicine doubles antibody response to COVID-19 boosterA major clinical trial, led by experts at the University of Nottingham working in partnership with several universities and NHS hospitals, has found that interrupting the treatment of vulnerable people on long-term immune-suppressing medicines for two weeks after a COVID-19 booster vaccination doubles their antibody response to the booster.
Read more »
Recombinant SARS-CoV-2 harboring double reporters for COVID-19 surveillanceIn a recent article posted to the bioRxiv* preprint server, researchers at Texas Biomedical Research Institute, Georgia State University, and the University of Alabama at Birmingham developed a bireporter-expressing recombinant severe acute respiratory syndrome coronavirus 2 (rSARS-CoV-2) for tracking SARS-CoV-2 infection.
Read more »
COVID-19 fattens up our body's cells to help fuel its viral takeover, study suggestsResearchers tried using weight-loss drugs and other fat-targeting compounds to try to stop the virus in cell culture. The new study comes as infections rose in all four UK nations, with about 1.7 million having the virus last week.
Read more »
A multisource database tracking the impact of the COVID-19 pandemic on the communities of Boston, MA, USA - Scientific DataMeasurement(s)Neighborhood contextTechnology Type(s)Naturally-occurring dataSample Characteristic - EnvironmentCity neighborhoodsSample Characteristic - LocationBoston, MA, USA
Read more »
COVID-19: People in France 'should wear masks again on public transport' as new coronavirus wave hits nationThe increase in coronavirus cases is being fuelled by new variants, with 17,601 new infections over the past 24 hours - the highest Monday figure since 18 April.
Read more »